The top 50 drugs by frequency of positive signals stratified by sex – by 4 methods (ROR PRR IC MGPS). -н Jun Hua Lai (22676523)

Нөхцлүүд:

Flowchart. -н Jun Hua Lai (22676523)

Нөхцлүүд:

The top 25 drugs sorted by frequency of positive signals stratified by age – by 4 methods (ROR PRR IC MGPS). -н Jun Hua Lai (22676523)

Нөхцлүүд:

The principles of disproportionate measurement and the criteria for signal detection. -н Jun Hua Lai (22676523)

Нөхцлүүд:

Participants in the multistakeholder dialogue. -н David Galibourg (22676459)

Нөхцлүүд:

How actors and their interactions influence farmers’ opportunity to use piped water. -н David Galibourg (22676459)

Нөхцлүүд:

Integrative conceptual framework for exploring institutions’ influence on stakeholders adopting safe practices to increase hygiene and food safety in the urban irrigated vegetable... -н David Galibourg (22676459)

Нөхцлүүд:

Relative Burden of Foodborne Disease, by per Capita Income, 2010 (adapted from Jaffee et al., 2019, p. 42). -н David Galibourg (22676459)

Нөхцлүүд:

Mean (SD) of Weight, TWL%, and EWL% for each postoperative follow-up point. -н Saleh Abualhaj (22683253)

Нөхцлүүд:

Postoperative outcomes (N = 82). -н Saleh Abualhaj (22683253)

Нөхцлүүд:

Baseline Characteristics of the Study Cohort (N = 82). -н Saleh Abualhaj (22683253)

Нөхцлүүд:

Mean BMI trend across six time points after Bariclip surgery. -н Saleh Abualhaj (22683253)

Нөхцлүүд:

Table. ANOVA Table (Type III tests). -н Saleh Abualhaj (22683253)

Нөхцлүүд:

Mean %TWL and %EWL across six time points after Bariclip surgery. -н Saleh Abualhaj (22683253)

Нөхцлүүд:

Schematic illustration of laparoscopic vertical clip gastroplasty using the nonadjustable BariClip system, showing the placement of the clip along the stomach to create a restricti... -н Saleh Abualhaj (22683253)

Нөхцлүүд:

Mean (SD) BMI and 95% confidence intervals for each postoperative follow-up point. -н Saleh Abualhaj (22683253)

Нөхцлүүд:

Association of a COVID-19 diagnosis with adverse events, cohort design, follow-up starting on the day after time 0. -н Shelby S. Fisher (22676406)

Нөхцлүүд:

Association of a COVID-19 diagnosis with adverse events, SCRI design, marketscan and medicare, follow-up starting on the day after time 0. -н Shelby S. Fisher (22676406)

Нөхцлүүд:

Eligibility assessment, covariate assessment, and follow-up windows relative to time 0 for the cohort design. -н Shelby S. Fisher (22676406)

Нөхцлүүд:

Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0. -н Shelby S. Fisher (22676406)

Нөхцлүүд: